Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, August 14, 2023
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
[ Mon, Aug 14th 2023
] - WOPRAI
Michael Ulz Maintained (YMAB) at Sell with Decreased Target to $5 on, Aug 14th, 2023
Michael Ulz of Morgan Stanley, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Sell with Decreased Target from $7 to $5 on, Aug 14th, 2023.
Michael has made no other calls on YMAB in the last 4 months.
There are 3 other peers that have a rating on YMAB. Out of the 3 peers that are also analyzing YMAB, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Alec Stranahan of "B of A Securities" Maintained at Hold with Increased Target to $12 on, Monday, May 15th, 2023
These are the ratings of the 2 analyists that currently disagree with Michael
- William Plovanic of "Canaccord Genuity" Maintained at Strong Buy with Increased Target to $22 on, Tuesday, July 25th, 2023
- David Nierengarten of "Wedbush" Upgraded from Hold to Buy and Increased Target to $13 on, Wednesday, May 10th, 2023
